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Abstract:  
Multiple sclerosis (MS), a leading cause of neurological disability is an inflammatory 
demyelinating disease of the central nervous system (CNS). The clinical course of MS is highly 
variable ranging from isolated neurologic episodes to frequently relapsing or progressive disease. 
Currently there are no effective treatments for progressive MS. The long-term goal of this project 
is to evaluate a novel therapeutic strategy for progressive MS. Under physiological conditions 
signaling via the transcription factor, nuclear factor-kappa B (NF-κB) and glucocorticoid (GC) 
stimulation pathways regulate the immuno-inflammatory responses of the CNS resident glial 
cells. While NF-κB induces transcriptional activation, signaling via GC receptor functions to 
suppress immune responses. Persistent activation of NF-κB in the glial cells precipitates 
neuronal degeneration and axonal loss characteristic of progressive MS. Interactome analysis 
between the GC and NF-κB pathways suggested a novel strategy to inhibit NF-κB. 
Glucocorticoid-induced leucine zipper (GILZ) is a GC inducible protein that binds p65, the 
functionally critical subunit of NF-κB, and prevent transactivation of pathological mediators. 
The sites of interaction are localized to the proline rich region of the GILZ protein and the p65 
transactivation domain. A 23 residue GILZ peptide prevented nuclear translocation of p65 and 
suppressed disease in an animal model of MS. Structurally GILZ peptide adopted polyproline 
type II (PPII) helical conformation, a favorable feature for drug development. The objective of 
this study is to optimize the lead peptide and develop drug like analogs. Specific features of the 
GILZ-p65 interactions were adapted in the design of over 25 GILZ analogs such that each 
exhibit optimum PPII helix, bind p65 transactivation domain and potentially accommodate 
modified residues that enhance the binding specificity with the p65. The analogs were ranked 
after passing through the Lipinski filter to determine the drug like properties. The top ranked 
analogs will be evaluated for functional efficacy. 
 
 
